What is personalised care in lung cancer?

Personalised care is **tailored to an individual** based on the lung cancer's **genetic information** and the person's **lifestyle** and **environment**[1,2]

A **better understanding** of lung cancers and **advances in cancer tests** has helped move care:[1–3]

From a traditional approach
- chemotherapy, radiotherapy and/or surgery
- based on lung cancer **location and stage**

To a precision approach
- personalised treatments
- based on lung cancer's **genetic information**

This marks an important step towards personalised care[1]

Biomarker testing is key

Testing your lung cancer to identify its **subtype** and **genetic information** (known as biomarkers) can help doctors select the best treatment[3,4]

Biopsy

A sample of **lung cancer cells are collected**[4,5]
- usually from **tissue** (solid tissue biopsy)
- sometimes from **fluid** e.g. blood (liquid biopsy)

Finding biomarkers

The sample can be **tested for biomarkers**[6]
- using **single biomarker tests** (detects one biomarker)
- or **comprehensive genomic profiling** (detects multiple biomarkers)

Personalised treatments

Targeted treatments and **immunotherapies** might be selected to target biomarkers[1,3,4,7]
- this means they may be **more effective** and have **fewer side effects** than traditional treatments
- but results aren't always conclusive

Ongoing testing and consenting to share your cancer's genetic information can help provide the best treatment to you and others[1,8]

This material is released under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license (CC BY-NC-SA 4.0). You may share (copy and redistribute) and adapt (remix, transform, and build upon) this. However you must give appropriate credit to Roche and its co-creation partners (its Global Personalised Healthcare Oncology Patient Council), a license notice, and a link to the original material as co-created in February 2022. If you build upon this material, you must distribute your version under the same license as the original (CC BY-NC-SA 4.0).

Veeva Document Number: M-XX-00007652
Date of prep: February 2022

References

1.European Society for Medical Oncology. Personalised Cancer Medicine: An ESMO Guide for Patients. [Internet; cited February 2022]. Available from: https://www.esmo.org/content/download/20122/337223/1/ESMO-Patient-Guide-Personalised-Cancer-Medicine.pdf

2.Lucy R Yates et al. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology, 2018, Volume 29, Pages 30–35. Available from: https://www.sciencedirect.com/science/article/pii/S0923753419350112

3.European Society for Medical Oncology. Personalised Medicine at a Glance: Lung Cancer. [Internet; cited February 2022]. Available from: https://www.esmo.org/for-patients/personalised-medicine-explained/Lung-Cancer

4.National Cancer Institute. Biomarker Testing for Cancer Treatment. [Internet; cited February 2022]. Available from: https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment

5.Cancer Research UK. Biopsy through the skin for lung cancer. [Internet; cited February 2022]. Available from: https://www.cancerresearchuk.org/about-cancer/lung-cancer/getting-diagnosed/tests/biopsy-through-skin

6.Roche. Genomic testing infographic. [Internet; cited February 2022]. Available from: https://www.roche.com/dam/jcr:9629a2ae-ed72-471b-bbca-f644479e8a56/en/PCTTT-genomic-testing-infographic.pdf

7.American Cancer Society. Precision or Personalized Medicine. [Internet; cited February 2022]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/precision-medicine.html

8.Charles River Associates. The benefits of personalised medicine to patients, society and healthcare systems. [Internet; cited February 2022]. Available from: https://www.crai.com/insights-events/publications/benefits-personalised-medicines-patients-society-and-healthcare-systems

The development of this material was supported by Roche. It has been provided to patient organisations for their use and adaptation and Roche accepts no liability once adapted.